Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT07107529

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Led by European Myeloma Network B.V. · Updated on 2026-04-15

150

Participants Needed

29

Research Sites

424 weeks

Total Duration

On this page

Sponsors

E

European Myeloma Network B.V.

Lead Sponsor

E

EMN Trial Office S.r.l. Impresa Sociale

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multicenter, open-label phase II study with 2 parallel cohorts for frail patients with newly diagnosed multiple myeloma treated with daratumumab in combination with teclistamab and talquetamab. The main purpose of this study is to determine the progression free survival at 18 months in patients treated with teclistamab and daratumumab (Cohort 1) or talquetamab and daratumumab (Cohort 2).

CONDITIONS

Official Title

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patient is 18 years of age or older and capable of giving informed consent
  • Newly diagnosed and treatment-naive with confirmed multiple myeloma and measurable disease per IMWG criteria
  • Measurable disease defined as M-protein in serum (≥1 g/dL) or serum free light chain assay ≥10 mg/dL with abnormal kappa/lambda ratio
  • Frail according to the Simplified IMWG frailty index
  • Clinical laboratory values within defined ranges
  • Patients of childbearing potential agree to use highly effective contraception from consent until 3 months after last study drug dose
Not Eligible

You will not qualify if you...

  • Non-secretory multiple myeloma or measurable disease only by urine or plasmacytoma
  • Central nervous system involvement of myeloma
  • Significant lung dysfunction
  • Stroke, transient ischemic attack, or seizure within 6 months prior
  • Active systemic viral, fungal, or bacterial infections requiring systemic treatment
  • HIV or hepatitis infections
  • History of other malignancies at high risk of recurrence requiring treatment or treated with chemotherapy affecting bone marrow capacity
  • Any active malignancy other than multiple myeloma requiring treatment change in last 24 months
  • Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months
  • Life-threatening allergies or intolerance to study treatments
  • Extensive radiotherapy within 14 days or focal radiation within 7 days
  • Current or recent multiple myeloma therapy or corticosteroids >40 mg dexamethasone equivalent within 14 days
  • Received live attenuated vaccine within 4 weeks prior
  • Use of strong CYP3A4 inducers or St. John's wort within 5 half-lives prior
  • Major surgery or significant trauma within 2 weeks prior (except kyphoplasty or vertebroplasty)
  • Received investigational drugs or invasive devices within 4 weeks prior except long-term survival data collection
  • Medical or psychiatric conditions interfering with study participation or safety
  • Any other condition that would impair ability to receive treatment, understand consent, or complete assessments

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 29 locations

1

IT-Ascoli Piceno-Ospedale Mazzoni [01-016]

Ascoli Piceno, Italy

Actively Recruiting

2

IT-Bari-A.O.U. Consorziale Policlinico - Medicina Interna [01-018]

Bari, Italy

Not Yet Recruiting

3

IT-Bergamo-A.O. Papa Giovanni XXIII [01-003]

Bergamo, Italy

Not Yet Recruiting

4

IT-Bologna-A.O.U. di Bologna - Policlinico S. Orsola Malpighi [01-004]

Bologna, Italy

Not Yet Recruiting

5

IT-Bolzano-Ospedale di Bolzano - Azienda Sanitaria dell'Alto Adige [01-021]

Bolzano, Italy

Not Yet Recruiting

6

IT-Como-Ospedale Classificato Valduce [01-104]

Como, Italy

Actively Recruiting

7

IT-Milano-Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico [01-039]

Milan, Italy

Not Yet Recruiting

8

IT-Milano-Ospedale S. Carlo Borromeo [01-105]

Milan, Italy

Actively Recruiting

9

IT-Novara-A.O.U. Maggiore della Carità [01-010]

Novara, Italy

Actively Recruiting

10

IT-Pescara-Azienda USL di Pescara P.O. dello Spirito Santo [01-053]

Pescara, Italy

Actively Recruiting

11

IT-Roma-ASL Roma 1 [01-101]

Roma, Italy

Not Yet Recruiting

12

IT-Roma-Policlinico Umberto I - Università 'Sapienza' [01-013]

Roma, Italy

Not Yet Recruiting

13

IT-Torino-A.O.U. Città della Salute e della Scienza di Torino-SSD Clinical trials [01-001]

Torino, Italy

Not Yet Recruiting

14

IT-Varese-Ospedale di Circolo [01-111]

Varese, Italy

Not Yet Recruiting

15

NL-Amsterdam-Vrije Universiteit Medical Center (VUMC) [02-007]

Amsterdam, Netherlands

Not Yet Recruiting

16

NL-Arnhem-Rijnstate Hospital [02-009]

Arnhem, Netherlands

Not Yet Recruiting

17

NL-Enschede-Medisch Spectrum Twente [02-024]

Enschede, Netherlands

Not Yet Recruiting

18

NL-Groningen-University Medical Center Groningen [02-030]

Groningen, Netherlands

Not Yet Recruiting

19

NL-Nieuwegein-S. Antonius Hospital [02-038]

Nieuwegein, Netherlands

Not Yet Recruiting

20

NL-Schiedam-Franciscus Vlietland Hospital [02-049]

Schiedam, Netherlands

Not Yet Recruiting

21

NL-Sittard-Geleen-Zuyderland Medical Center [02-058]

Sittard, Netherlands

Not Yet Recruiting

22

NL-Den Haag-Haga Ziekenhuis [02-016]

The Hague, Netherlands

Not Yet Recruiting

23

NL-Zwolle-Isala Klinieken [02-057]

Zwolle, Netherlands

Not Yet Recruiting

24

NO-Oslo-Oslo University Hospital [23-007]

Oslo, Norway

Not Yet Recruiting

25

NO-Tønsberg-Vestfold Hospital Trust [23-012]

Tønsberg, Norway

Not Yet Recruiting

26

ES-Barcelona-H.U. Vall d'Hebrón [06-002]

Barcelona, Spain

Not Yet Recruiting

27

ES-Las Palmas-H.U. de Gran Canaria Dr Negrín [06-030]

Las Palmas, Spain

Not Yet Recruiting

28

ES-Murcia-H.U. Virgen de la Arrixaca [06-016]

Murcia, Spain

Actively Recruiting

29

ES-Salamanca-H.U. de Salamanca [06-021]

Salamanca, Spain

Not Yet Recruiting

Loading map...

Research Team

C

Clinical Trial Office

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here